Dynavax Technologies reported $219.96M in Loan Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Adma Biologics ADMA:US $ 93.88M 0.46M
Agenus AGEN:US $ 18.95M 0.03M
Alexion Pharmaceuticals ALXN:US $ 2388.8M 30.8M
Amgen AMGN:US $ 28458M 2671M
AstraZeneca AZN:LN 24601M 6727M
Astrazeneca AZN:US 24.6B 6.73B
Biogen BIIB:US $ 7269.2M 2M
Biomarin Pharmaceutical BMRN:US $ 1077.11M 0.98M
BioSpecifics Technologies BSTC:US 0 0
Bristol Myers Squibb BMY:US $ 42503M 2002M
Chimerix CMRX:US $ 0 0
Dynavax Technologies DVAX:US $ 219.96M 40.07M
Glaxosmithkline GSK:US $ 20442M 2605M
Gw Pharmaceuticals GWPH:US $ 14.16M 0.14M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 326.3M 4.3M
Novartis NOVN:VX SF 26491M 908M
Regeneron Pharmaceuticals REGN:US $ 1979.2M 0.3M
Sarepta Therapeutics SRPT:US $ 1092.98M 1.88M
Vertex Pharmaceuticals VRTX:US $ 524.92M 5.4M